October 11, 2025Open Access

Sotatercept Improves Small Airway Disease and Hyperinflation in Patients with Pulmonary Hypertension

View Full Paper

Ask AI

Bookmark

Sotatercept treatment significantly improved FEV1 by 155 mL, indicating enhanced lung function in patients with pulmonary hypertension.
Participants experienced increases in FVC by 180 mL and decreases in RV of 210 mL, marking crucial improvements in lung capacity.
This retrospective cohort study involved 48 patients receiving sotatercept, assessing changes through pulmonary function tests pre-and post-treatment.
Overall, findings highlight that sotatercept may be beneficial for reducing small airway disease and hyperinflation in precapillary pulmonary hypertension.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective cohort study shows sotatercept improves small airway disease and hyperinflation in patients with pulmonary hypertension.

Poor et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark